Truveta brand logo mark in teal on a black background, featuring stacked chevron shapes forming the Truveta symbol.

Following semaglutide (Wegovy) as a new MASH treatment with Truveta Data

by | Nov 18, 2026

  • Novo Nordisk presented two studies at The Liver Meeting 2026 that used Truveta Data to examine changes in liver enzymes, weight, and blood sugar among adults with metabolic dysfunction-associated steatohepatitis (MASH) who started semaglutide 2.4 mg (Wegovy). 
  • In PLATINUM-Truveta, adults who started semaglutide had a larger drop in a key marker of liver injury at six months than adults who started resmetirom, along with greater improvements in weight and blood sugar. 
  • In RHODIUM-2, adults who started semaglutide had larger 12-month reductions in liver enzymes and weight than adults with MASH who did not start it. 

Semaglutide 2.4 mg (Wegovy), a once-weekly GLP-1 injection first approved for weight management, received accelerated approval to treat MASH in August 2025. It joined resmetirom, a separate once-daily pill that became the first medication approved for MASH in 2024. Accelerated approval allows promising treatments to reach patients sooner, while longer trials continue to confirm their benefit. That leaves an important question in the meantime about how patients respond once a therapy moves from approval into clinical practice. 

To begin answering that question, Novo Nordisk researchers used de-identified electronic health record (EHR) data from Truveta to study adults with MASH who started semaglutide. The two studies, presented at The Liver Meeting 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), drew on lab results, body weight, and other clinical measures recorded during routine care. 

Comparing two approved MASH treatments 

PLATINUM-Truveta compared adults with MASH who started semaglutide with those who started resmetirom (1). After six months, the semaglutide group had a significantly greater reduction in aspartate aminotransferase, a liver enzyme that rises when the liver is damaged. Adults who started semaglutide also lost about 8% of their body weight on average and had better blood sugar control, while resmetirom was associated with a larger reduction in low-density lipoprotein cholesterol. 

Comparing patients who did and did not start semaglutide 

RHODIUM-2 compared adults with MASH who started semaglutide with those who did not (2). Over 12 months, the semaglutide group had greater reductions in two key liver enzymes, along with greater weight loss and a larger decrease in blood sugar. 

Following a new indication in real-world care 

Studying a new indication takes more than knowing who received a prescription. Researchers followed the same patients over time, connecting MASH diagnoses and medication history with lab results and body weight measured at three, six, and 12 months. That level of clinical detail also allowed them to exclude patients with cirrhosis or other liver diseases and to include only those who stayed on treatment.

Both studies were observational and show associations rather than causality. Treatment was not randomized, the groups differed at baseline, and follow-up was relatively short. As more patients start these treatments, real-world data could help show whether these early changes hold over time.

Citations 

  1. Arora P, Shi D, Aly A, et al. Real-world comparative effectiveness of semaglutide versus resmetirom on liver enzymes and cardiometabolic markers in patients with MASH. Presented at: The Liver Meeting 2026; November 6, 2026; Denver, CO. Abstract 2461. 
  1. Albarmawi H, Shi D, Aly A, et al. Semaglutide 2.4 mg and the changes in liver enzymes and cardiometabolic markers in patients with MASH: a descriptive real-world data study. Presented at: The Liver Meeting 2026; November 6, 2026; Denver, CO. Abstract 2473. 

Recent posts

Follow Truveta

Stay up-to-date